Stocks and Investing
Stocks and Investing
Wed, October 5, 2016
[ 01:45 PM ] - United States, WOPRAI
[ 01:45 PM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 11:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Biren Amin Maintained (VRTX) at Strong Buy with Increased Target to $105 on, Oct 5th, 2016
Biren Amin of Jefferies, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $104 to $105 on, Oct 5th, 2016.
Biren has made no other calls on VRTX in the last 4 months.
There are 2 other peers that have a rating on VRTX. Out of the 2 peers that are also analyzing VRTX, 1 agrees with Biren's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Christopher Raymond of "Raymond James" Initiated at Hold on, Tuesday, September 13th, 2016
This is the rating of the analyst that currently disagrees with Biren
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $139 on, Thursday, July 28th, 2016
Contributing Sources